SBIR/STTR Research Award
Novel NMDA Antagonists Lacking PCP Like Side Effects
Award amount
$75,817Program and phase
SBIR · Phase IAward year
1995Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- NPS Pharmaceuticals, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
NMDA receptor antagonists may possess therapeutic utility for a variety of CNS pathologies, but NMDantagonists may elicit side effects including PCP-like psychotomimetic episodes. Early Araxin compouNPS antagonize NMDA receptors at a unique site and by a novel mechanism, possess therapeutic utilityCNS disease, and do not elicit a PCP-like behavioral profile in rodents. Hypotension, elicited by eahowever, halted their further development. NPS has recently discovered a new class of compounds, basAraxin compounds, but simplified chemically, which retain high potency against NMDA receptors. The cexemplified by NPS 846, are termed "NPS 846 generation Araxin compounds". Preliminary results demons846 possesses anticonvulsant and neuroprotectant activity, but does not elicit cardiovascular effectThese studies will confirm and expand upon these preliminary findings.
Technology keywords
Not reported